Cybin Inc.

NYSE American CYBN

Cybin Inc. EBIT for the year ending March 31, 2024: USD -58.20 M

Cybin Inc. EBIT is USD -58.20 M for the year ending March 31, 2024, a -52.72% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Cybin Inc. EBIT for the year ending March 31, 2023 was USD -38.11 M, a 25.31% change year over year.
Cybin Inc. EBIT for the year ending March 31, 2022 was USD -51.02 M, a -99.03% change year over year.
Cybin Inc. EBIT for the year ending March 31, 2021 was USD -25.63 M, a -1,755.70% change year over year.
Cybin Inc. EBIT for the year ending March 31, 2020 was USD -1.38 M, a -654.10% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

NYSE American: CYBN

Cybin Inc.

CEO	Mr. Douglas L. Drysdale
IPO Date	Sept. 13, 2019
Location	Canada
Headquarters	100 King Street West
Employees	50
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Key trends

Past 5 years